Actavis launches Anastrozole on day one in seven major European markets
Actavis Group, the international generic pharmaceuticals company, today announced the launch Anastrozole Actavis in the UK, Germany, Netherlands, Ireland, Italy, Sweden and Finland immediately after the patent expired on 11 and 12 February, respectively.
Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women. Anastrozole Actavis is the generic equivalent of AstraZeneca‘s brand product Arimidex®
The brand sold for EUR492 million in Europe for the twelve month period ended September 2010. (IMS Health).
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.